EE+ POEM Archive
Passive infant immunization with nirsevimab is more effective than maternal RSV vaccine for lowering adverse RSV-related outcomes in newborns
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Passive Infant Immunization With Nirsevimab Is More Effective Than Maternal RSV Vaccine for Lowering Adverse RSV-related Outcomes in Newborns." EE+ POEM Archive, John Wiley & Sons, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377564/all/Passive_infant_immunization_with_nirsevimab_is_more_effective_than_maternal_RSV_vaccine_for_lowering_adverse_RSV_related_outcomes_in_newborns.
Passive infant immunization with nirsevimab is more effective than maternal RSV vaccine for lowering adverse RSV-related outcomes in newborns. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377564/all/Passive_infant_immunization_with_nirsevimab_is_more_effective_than_maternal_RSV_vaccine_for_lowering_adverse_RSV_related_outcomes_in_newborns. Accessed March 8, 2026.
Passive infant immunization with nirsevimab is more effective than maternal RSV vaccine for lowering adverse RSV-related outcomes in newborns. (2026). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377564/all/Passive_infant_immunization_with_nirsevimab_is_more_effective_than_maternal_RSV_vaccine_for_lowering_adverse_RSV_related_outcomes_in_newborns
Passive Infant Immunization With Nirsevimab Is More Effective Than Maternal RSV Vaccine for Lowering Adverse RSV-related Outcomes in Newborns [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2026. [cited 2026 March 08]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377564/all/Passive_infant_immunization_with_nirsevimab_is_more_effective_than_maternal_RSV_vaccine_for_lowering_adverse_RSV_related_outcomes_in_newborns.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Passive infant immunization with nirsevimab is more effective than maternal RSV vaccine for lowering adverse RSV-related outcomes in newborns
ID - 3377564
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377564/all/Passive_infant_immunization_with_nirsevimab_is_more_effective_than_maternal_RSV_vaccine_for_lowering_adverse_RSV_related_outcomes_in_newborns
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
